Initiates Coverage on Isoray (NYSE:ISR) assumed coverage on shares of Isoray (NYSE:ISRGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Isoray Price Performance

NYSE:ISR opened at $0.28 on Tuesday. The company has a 50 day moving average price of $0.31 and a 200-day moving average price of $0.33. Isoray has a 1-year low of $0.19 and a 1-year high of $0.45. The firm has a market cap of $39.76 million, a price-to-earnings ratio of -4.66 and a beta of 1.38.

Isoray Company Profile

(Get Rating)

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

Further Reading

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with's FREE daily email newsletter.